PROTOCOL CNP520A2202J, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF05/01/2018 - 04/30/2025 (PI)
Novartis Pharmaceuticals Corporation
PROTOCOL API015A2201J, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO COHORT PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY OF CAD106 AND CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL02/01/2018 - 08/31/2024 (PI)
Novartis Pharmaceuticals Corporation
CHRONIC TRAUMATIC ENCEPHALOPATHY: DETECTION, DIAGNOSIS, COURSE, AND RISK FACTORS12/15/2015 - 11/30/2022 (PI)
NIH/National Institute of Neurological Disorders & Stroke5U01NS093334-03
REGISTRY OF AMYLOID POSITIVE PATIENTS FOR ALZHEIMER'S DISEASE DRUG RESEARCH TRIALS ( RAMP OR 18F-AV-45-A25)03/20/2017 - 03/19/2020 (PI)
Avid Radiopharmaceuticals, Inc.
ALZHEIMER'S DISEASE COOPERATIVE STUDY - A4 STUDY12/01/2015 - 02/28/2019 (PI)
University of Southern California NIH NIA4U19AG010483-26
TAU PET IMAGING FOR THE USC ALZHEIMER'S THERAPEUTIC RESEARCH INSTITUTE (USC ATRI) A4 TRIAL ( A4 TAU )10/01/2016 - 12/31/2018 (PI)
University of Southern California Fundation for NIH
A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, BAYESIAN ADAPTIVE RANDOMIZATION DESIGN AND DOSE REGIMEN-FINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND EFFICACY OF BAN2401 IN SUBJECTS WITH02/01/2013 - 12/31/2018 (PI)
Eisai, Inc
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER'S DISEASE (A4 STUDY)12/11/2015 - 12/10/2018 (PI)
University of Southern California Eli Lilly and Co
LONGITUDINAL EVALUATION OF AMYLOID RISK AND NEURODEGENERATION - THE LEARN STUDY11/01/2015 - 10/31/2018 (PI)
University of Southern California Alzheimer's Assoc
AN OPEN LABEL, MULTICENTER STUDY EVALUATING THE IMAGING CHARACTERISTICS OF A FOLLOW UP F-AV-1451 SCAN IN SUBJECTS THAT PARTICIPATED IN THE CONFIRMATORY COHORT OF FV-AV-1451-A0509/29/2016 - 09/28/2018 (PI)
Avid Radiopharmaceuticals, Inc.
Showing 10 of 42 results.
Show All Results
MEASURING GLIAL METABOLISM IN REPETITIVE BRAIN TRAUMA AND ALZHEIMER'S DISEASE08/15/2015 - 08/14/2018 (PI)
The Brigham and Women's Hospital, Inc. DOD Army Med Resrch
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMER'S DISEASE DEMENTIA (THE DAYBREAK STUDY)10/24/2016 - 06/12/2018 (PI)
Eli Lilly and Company
AN OPEN LABEL, MULTICENTER STUDY, EVALUATING THE SAFETY AND IMAGING CHARACTERISTICS OF 18F-AV-1451 IN COGNITIVELY HEALTHY VOLUNTEERS, SUBJECTS WITH MILD COGNITIVE IMPAIRMENT, AND SUBJECTS WITH ALZHEIM03/01/2014 - 05/31/2018 (PI)
Avid Radiopharmaceuticals, Inc.
A PHASE 2 MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF T-817MA IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE (US202)11/21/2013 - 05/31/2018 (PI)
The Regents of the University of California Toyama Chemical Co.
PROTOCOL 54861911ALZ2003, A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY INVESTIGATION THE EFFICACY AND SAFETY OF JNJ-54861911 IN SUBJECTS WHO ARE ASYMP10/27/2017 - 05/17/2018 (PI)
Janssen Research & Development, LLC
MAGNETIC RESONANCE SPECTROSCOPY AS A BIOMARKER FOR CHRONIC TRAUMATIC ENCEPHALOPATHY05/01/2016 - 04/30/2018 (Co-PI)
PI:
Michael Alosco, PhDNIH/National Institute of Neurological Disorders & Stroke5F32NS096803-02
EFFECT OF PASSIVE IMMUNIZATION ON THE PROGRESSION OF MILD ALZHEIMER'S DISEASE: SOLANEZUMAB (LY2062430) VERSUS PLACEBO12/01/2013 - 04/30/2017 (PI)
Eli Lilly and Company
DOD TRAUMATIC BRAIN INJURY RESEARCH AWARD09/30/2013 - 09/29/2016 (PI)
Department of Defense
AMARANTUS LYMPRO CELL CYCLE DYSFUNCTION BLOOD BIOMARKER FOR AD AND CTE06/16/2014 - 06/15/2016 (PI)
Amarantus Holdings, Inc.
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER'S DISEASE (STUDY A4)12/31/2012 - 05/31/2016 (PI)
University of California, San Diego NIH NIA5U01AG010483-24
RISK OF COGNITIVE DECLINE IN OLDER BREAST CANCER PATIENTS10/01/2009 - 04/30/2016 (PI)
Georgetown University NIH NCI5R01CA129769-05
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER'S DISEASE (STUDY A4)12/31/2012 - 04/27/2016 (PI)
University of California, San Diego NIH NIA5U01AG010483-24
CHRONIC TRAUMATIC ENCEPHALOPATHY: CLINICAL PRESENTATION AND BIOMARKERS09/30/2014 - 02/29/2016 (PI)
NIH/National Institute of Neurological Disorders & Stroke2R56NS078337-04
18F-AV-1451 AND FLORBETAPIR F 18 PET IMAGING IN SUBJECTS WITH REPETITIVE BRAIN TRAUMA AT HIGH RISK FOR CHRONIC TRAUMATIC ENCEPHALOPATHY03/01/2014 - 09/01/2015 (PI)
Avid Radiopharmaceuticals, Inc.
DIAGNOSING AND EVALUATING TRAUMATIC ENCEPHALOPATHY USING CLINICAL TESTS01/01/2012 - 12/31/2014 (PI)
Brainscope Company, Inc
DIAGNOSING AND EVALUATING TRAUMATIC ENCEPHALOPATHY USING CLINICAL TESTS01/01/2012 - 12/31/2014 (PI)
Brainscope Company, Inc
A PHASE 3 EXTENSION, MULTICENTER, LONG-TERM SAFETY AND TOLERABILITY TRIAL OF BAPINEUZUMAB (AAB-001, ELN115727) IN SUBJECTS WITH ALZHEIMER DISEASE WHO ARE APOLIPOPROTEIN E E4 CARRIERS AND PARTICIPATED12/01/2011 - 11/30/2014 (PI)
Pfizer, Inc.
CHRONIC TRAUMATIC ENCEPHALOPATHY: CLINICAL PRESENTATION AND BIOMARKERS08/01/2011 - 09/29/2014 (PI)
NIH/National Institute of Neurological Disorders & Stroke5R01NS078337-03
SUBCLINICAL HYPOTHYROIDISM: MOOD, COGNITION AND THE EFFECT OF L-THYROXINE TREATMENT09/30/2008 - 05/31/2014 (PI)
NIH/National Institute of Mental Health5R01MH080295-05
CONCERT PLUS: AN OPEN-LABEL EXTENSION OF THE CONCERT PROTOCOL (DIM18) EVALUATING DIMEBON (LATERPIRDINE) IN PATIENTS WITH ALZHEIMER'S DISEASE PHASE 3 MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED,08/01/2010 - 07/31/2013 (PI)
Medivation, Inc.
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP EFFICACY SAFETY TRIAL OF BAPINEVZUMB (AAB-001, ELN115727) IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER DISEASE05/01/2011 - 04/30/2013 (PI)
Wyeth Pharmaceuticals
A PHASE 3, MULTICENTER, PARALLEL-GROUP, LONG TERM SAFETY AND TOLERABILTY TREATMENT TRIAL OF BAPINEUZUMAB (AAB-001), ELN115727) IN SUBJECTS WITH AD WHO PARTICIPATED IN STUDY ELN115727-301 OR IN ST12/01/2009 - 04/30/2013 (PI)
Janssen Pharmaceutica (Belgium)
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF BAPINEUZUMAB11/01/2009 - 04/30/2013 (PI)
Wyeth Pharmaceuticals
ADCS INFRASTRUCTURE SUPPORT01/01/2012 - 12/31/2012 (PI)
The Regents of the University of California NIH NIAAG010483-21
MULTI-CENTRIAL TO EVALUATE HOME-BASED ASSESSMENT METHODS FOR ALZHEIMER'S DISEASE PREVENTION RESEARCH IN PEOPLE OVER 75 YEARS OLD09/01/2007 - 12/31/2012 (PI)
University of California, San Diego NIH NIA
PREVENTION OF ALZHEIMER'S DISEASE AND COGNITIVE DECLINE09/01/2009 - 07/31/2012 (PI)
Seattle Institute for Biomedical and Clinical Research NIH NIA
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY TRIAL OF BAPINEUZUMAB (AAB-001, ELN115727) IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S04/01/2008 - 03/31/2012 (PI)
Elan Pharmaceuticals, Inc.
ASSESSMENT OF DRIVING SAFETY IN AGING, MCI AND DEMENTIA03/01/2009 - 02/29/2012 (PI)
Alzheimer's Association
OBJECTIVE BIOMARKERS FOR ALZHEIMER'S DISEASE IN THE RETINA12/01/2009 - 11/30/2011 (PI)
Mass Eye and Ear Infirmary Other Fdns/Societies
EFFECT OF GAMA SECTRETASE INHIBITION ON THE PROGRESSION ON AD: LY 450139 VERSUS PLACEBO, CONTROL H6L-MC-LFAN12/01/2008 - 11/30/2011 (PI)
Eli Lilly and Company, Lilly Research Laboratories
Effect of Gamma Secretase Inhibition on the Progression on AD: LY 450139 Versus Placebo, Control H6L-MC-LFAN12/01/2008 - 11/30/2011 (PI)
Lilly Research Laboratories (Division of Eli Lilly and Company)
Driving and Dementia11/01/2004 - 10/31/2006 (PI)
Massachusetts Institute of Technology Hartford Fin Svcs Gr